Research Analysts Set Expectations for Halozyme Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research boosted their Q1 2025 earnings estimates for shares of Halozyme Therapeutics in a research report issued on Monday, September 23rd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.93 for the quarter, up from their prior estimate of $0.92. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.71 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.40 EPS, Q2 2026 earnings at $1.48 EPS and FY2026 earnings at $5.90 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. During the same quarter last year, the business earned $0.68 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year.

Other research analysts also recently issued reports about the company. Piper Sandler downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $48.00 to $51.00 in a research note on Friday, June 7th. TD Cowen boosted their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Benchmark reiterated a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of Halozyme Therapeutics in a report on Friday, September 13th. Finally, Wells Fargo & Company increased their price target on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $56.95 on Wednesday. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. The stock’s 50 day simple moving average is $58.61 and its 200-day simple moving average is $49.57. The company has a market cap of $7.25 billion, a PE ratio of 23.53, a price-to-earnings-growth ratio of 0.56 and a beta of 1.28. Halozyme Therapeutics has a 1-year low of $32.83 and a 1-year high of $65.53.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $56.34, for a total transaction of $563,400.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $38,127,756.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $56.34, for a total value of $563,400.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $38,127,756.96. The disclosure for this sale can be found here. Insiders have sold 84,881 shares of company stock worth $4,932,284 over the last quarter. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its holdings in Halozyme Therapeutics by 9.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock valued at $59,622,000 after acquiring an additional 145,879 shares during the period. Janney Montgomery Scott LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $473,000. Norges Bank purchased a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $44,935,000. Corient Private Wealth LLC lifted its holdings in Halozyme Therapeutics by 17.2% during the 4th quarter. Corient Private Wealth LLC now owns 21,881 shares of the biopharmaceutical company’s stock worth $809,000 after buying an additional 3,206 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV purchased a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $236,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.